Apimeds Pharmaceuticals US, Inc. filed a Current Report on Form 8-K disclosing the execution of an amendment to its Confidential Settlement and Mutual Release Agreement dated September 10, 2026. The amendment restructures the company's board composition, establishing an interim board of four directors who cannot be removed without consent from Dr. Vin Menon and the Inscobee Parties. Following this period, the board will expand to seven members, including independent directors nominated by MindWave Innovations Inc., two nominees from Dr. Menon (one being himself), and Sungjoon Chae. Concurrently, Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to nominations by the Inscobee Parties under the settlement terms. Mr. Chae has served as Co-Chief Executive Officer since May 4, 2026 and holds degrees from the Illinois Institute of Technology and Harvard University with expertise in urban design and real estate development. Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, focusing on drug discovery and development.

On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc., acquiring specific rights to its lead asset, Apitox. The transaction grants the company 100% of rights for the Korean medicine clinic market in South Korea, a 25% royalty entitlement on U.S. economic proceeds from development or commercialization, and a 25% revenue participation right on net proceeds from overseas licensing agreements. Additionally, Apimeds secured rights to quarterly clinical progress updates and certain manufacturing data benefits. The company confirmed these assigned rights are free of prior encumbrances and assumes no pre-existing liabilities of FreeT. This strategic acquisition expands the company's intellectual property portfolio and potential revenue streams for its proprietary bee venom-based therapeutic candidate. Apimeds Pharmaceuticals US, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics derived from apitoxin.

On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as its Chief Scientific Officer, effective immediately. In this role, Dr. Kim will lead the scientific, clinical, and regulatory development of the company's APITOX program, overseeing research, clinical strategy, and regulatory engagement to advance the asset toward commercialization. The appointment provides continuity in leadership for a program with which Dr. Kim has been closely associated for many years. Apimeds Pharmaceuticals US, Inc. operates in the pharmaceutical industry, focusing on drug development.

Apimeds Pharmaceuticals US, Inc. announced that it will effect a 1-for-10 reverse stock split of its common stock. The company expects to file the necessary Charter Amendment with the Delaware Secretary of State on or about July 23, 2026, with the split becoming effective at 12:01 a.m. Eastern Time on July 24, 2026. Common stock is expected to trade on a split-adjusted basis on the NYSE American under the symbol "APUS" starting July 24, 2026, with a new CUSIP number of 03771D201. This replaces a previously announced effective date of March 26, 2026. The company operates in the pharmaceutical industry and develops medical treatments.